Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes

Mark W Stolar,1 Michael Grimm,2 Steve Chen2 1Clinical Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Amylin Pharmaceuticals, LLC, San Diego, CA, USA Abstract: Exenatide once weekly (EQW), the first glucose-lowering agent for type 2 diabetes that is dosed one time p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stolar MW, Grimm M, Chen S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/f96844b882ed41e1a97c974166290ed4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f96844b882ed41e1a97c974166290ed4
record_format	dspace
spelling	oai:doaj.org-article:f96844b882ed41e1a97c974166290ed42021-12-02T04:09:53ZComparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes1178-7007https://doaj.org/article/f96844b882ed41e1a97c974166290ed42013-11-01T00:00:00Zhttp://www.dovepress.com/comparison-of-extended-release-glp-1-receptor-agonist-therapy-versus-s-a15057https://doaj.org/toc/1178-7007Mark W Stolar,1 Michael Grimm,2 Steve Chen2 1Clinical Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Amylin Pharmaceuticals, LLC, San Diego, CA, USA Abstract: Exenatide once weekly (EQW), the first glucose-lowering agent for type 2 diabetes that is dosed one time per week, contains exenatide encapsulated in microspheres of a dissolvable matrix, which release active agent slowly and continuously into the circulation following subcutaneous injection. In two direct head-to-head comparisons, EQW resulted in better long-term glucose control, greater reductions in fasting plasma glucose, and more significant weight loss than sitagliptin. In other trials, glucose-lowering effects of EQW compared favorably with those of metformin, pioglitazone, and basal insulin. Patients on EQW exhibited a higher incidence of nausea than those on sitagliptin, although gastrointestinal adverse events occurred primarily during the first 6–8 weeks of therapy and declined thereafter. EQW was also associated with a lower incidence of nausea than two other glucagon-like peptide-1 receptor agonists, exenatide twice daily and liraglutide. Mild hypoglycemic episodes were uncommon with EQW, although risk of hypoglycemia increased in combination with sulfonylureas. When choosing between EQW and a dipeptidyl peptidase-4 (DPP-4) inhibitor, such as sitagliptin, clinicians and patients should consider the differences between the two medications in terms of glucose control (EQW superior to DPP-4 inhibitors), weight control (EQW superior to DPP-4 inhibitors), gastrointestinal tolerability during treatment initiation (EQW inferior to DPP-4 inhibitors), and mode of administration (once-weekly subcutaneous administration versus once-daily oral administration). Keywords: exenatide, glucagon-like peptide 1, dipeptidyl peptidase-4 inhibitorsStolar MWGrimm MChen SDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2013, Iss default, Pp 435-444 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Stolar MW Grimm M Chen S Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
description	Mark W Stolar,1 Michael Grimm,2 Steve Chen2 1Clinical Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Amylin Pharmaceuticals, LLC, San Diego, CA, USA Abstract: Exenatide once weekly (EQW), the first glucose-lowering agent for type 2 diabetes that is dosed one time per week, contains exenatide encapsulated in microspheres of a dissolvable matrix, which release active agent slowly and continuously into the circulation following subcutaneous injection. In two direct head-to-head comparisons, EQW resulted in better long-term glucose control, greater reductions in fasting plasma glucose, and more significant weight loss than sitagliptin. In other trials, glucose-lowering effects of EQW compared favorably with those of metformin, pioglitazone, and basal insulin. Patients on EQW exhibited a higher incidence of nausea than those on sitagliptin, although gastrointestinal adverse events occurred primarily during the first 6–8 weeks of therapy and declined thereafter. EQW was also associated with a lower incidence of nausea than two other glucagon-like peptide-1 receptor agonists, exenatide twice daily and liraglutide. Mild hypoglycemic episodes were uncommon with EQW, although risk of hypoglycemia increased in combination with sulfonylureas. When choosing between EQW and a dipeptidyl peptidase-4 (DPP-4) inhibitor, such as sitagliptin, clinicians and patients should consider the differences between the two medications in terms of glucose control (EQW superior to DPP-4 inhibitors), weight control (EQW superior to DPP-4 inhibitors), gastrointestinal tolerability during treatment initiation (EQW inferior to DPP-4 inhibitors), and mode of administration (once-weekly subcutaneous administration versus once-daily oral administration). Keywords: exenatide, glucagon-like peptide 1, dipeptidyl peptidase-4 inhibitors
format	article
author	Stolar MW Grimm M Chen S
author_facet	Stolar MW Grimm M Chen S
author_sort	Stolar MW
title	Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
title_short	Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
title_full	Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
title_fullStr	Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
title_full_unstemmed	Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
title_sort	comparison of extended release glp-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/f96844b882ed41e1a97c974166290ed4
work_keys_str_mv	AT stolarmw comparisonofextendedreleaseglp1receptoragonisttherapyversussitagliptininthemanagementoftype2diabetes AT grimmm comparisonofextendedreleaseglp1receptoragonisttherapyversussitagliptininthemanagementoftype2diabetes AT chens comparisonofextendedreleaseglp1receptoragonisttherapyversussitagliptininthemanagementoftype2diabetes
_version_	1718401406894866432

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes

Ejemplares similares